Skip to main content
S&P 5007,568.92+0.36%DOW51,786.72-0.38%NASDAQ25,372.01+0.83%BTC$76,826.00-0.35%ETH$2,260.42+0.17%GOLD$3,971.50+0.79%OIL$95.79-0.31%
Smart Investors Daily
SID Premium
AC

NASDAQ · ACXP

Acurx Pharmaceuticals, Inc.

Healthcare · Biotechnology

$1.07

Down-$0.05 (-4.67%)

Updated Nov 4, 2026, 1:42 AM

SID Score

2.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
2.38M
P/E ratio
-0.27
Dividend yield
0.00%
52-week range
$1.04 – $7.54
Volume
143.79K
Avg. volume
61.79K

Price performance · ACXP

ACXP price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Nov 2, 2026

ACXP closed at $1.07 after 20 trading sessions, down 18.32% for the selected period.

Last close
$1.07
Period change
-18.32%
Period low
$1.04
Period high
$1.31
Daily close
View OHLC price history
ACXP OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 2, 2026$1.08$1.12$1.0451$1.07143.79K
Oct 30, 2026$1.09$1.1026$1.035$1.0463.19K
Oct 29, 2026$1.06$1.11$1.06$1.0764.57K
Oct 28, 2026$1.08$1.0801$1.05$1.0761.18K
Oct 27, 2026$1.08$1.0961$1.05$1.0658.37K
Oct 26, 2026$1.12$1.135$1.0809$1.08564.39K
Oct 23, 2026$1.135$1.14$1.12$1.13522.15K
Oct 22, 2026$1.16$1.185$1.14$1.1426.54K
Oct 21, 2026$1.18$1.18$1.13$1.1520.96K
Oct 20, 2026$1.16$1.18$1.115$1.1468.3K
Oct 19, 2026$1.14$1.1458$1.10$1.1451.1K
Oct 16, 2026$1.18$1.1896$1.0688$1.10164.83K
Oct 15, 2026$1.20$1.2189$1.15$1.17101.5K
Oct 14, 2026$1.20$1.2198$1.15$1.1587.57K
Oct 13, 2026$1.29$1.29$1.20$1.2099.67K
Oct 12, 2026$1.28$1.30$1.25$1.2880.82K
Oct 9, 2026$1.24$1.28$1.24$1.2741.15K
Oct 8, 2026$1.281$1.281$1.24$1.2574.94K
Oct 7, 2026$1.32$1.3299$1.28$1.3078.04K
Oct 6, 2026$1.30$1.33$1.28$1.3142.2K

Latest ACXP news

The latest Smart Investors Daily articles mentioning ACXP.

Stock researchCompany · Overview

ACXP research

Overview

Company profile and research snapshot.

Company profile

Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
ACXP recent ratings
DateFirmRatingTarget
Sep 29, 2026HC Wainwright & Co.Buy—
Sep 30, 2025HC Wainwright & Co.Buy—
Aug 12, 2025HC Wainwright & Co.Buy—
Mar 19, 2025HC Wainwright & Co.Buy—
Jan 13, 2025HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 26, 2026

Acurx Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 12, 2026 Conference Call and Provide Business Update

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for serious and life threatening bacterial infections, announced today that the Company will discuss its third quarter 2026 financial results on Thursday, November 12, 2026 at 8:00 am ET before the U.S. financial markets open.

Yahoo · Oct 21, 2026

Acurx Announces Publication in ASM Confirming Data on its DNA pol IIIC Inhibitor Pipeline of Antibiotics Demonstrating a Potential Microbiome-Sparing Class Effect

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for serious and life-threatening bacterial infections, today announced publication in the ASM (American Society for Microbiology) Microbiology Spectrum journal of results of a study entitled: The effects of novel oral preclinical PolC inhibitor antibiotic candidates on the gut microbiome in a murine thigh infection model. These findings confirm in vi

Yahoo · Sep 29, 2026

Acurx Pharmaceuticals Announces First Patient Enrolled in PATHFINDER Clinical Trial of Ibezapolstat in Multiply-Recurrent C. difficile Infection

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced that the first patient has been enrolled in its new clinical trial (PATHFINDER) in patients with multiply recurrent C. difficile Infection (rCDI). This new, fully funded,PATHFINDER clinical trial is a pilot trial in approximately 20 patients with multiply-recurrent CDI (at least three episo

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By